Group 1 - The State Council Information Office held a press conference on the achievements of high-quality market regulation during the "14th Five-Year Plan" period [1] - The market regulatory authority reported a net increase of 33.946 million individual businesses [4] - The pharmaceutical industry in China ranks third globally in terms of scale [6] Group 2 - Since the beginning of the "14th Five-Year Plan," a total of 387 children's medicines and 147 rare disease medicines have been approved for market, effectively meeting the medication needs of key populations [9]

Core Insights - The article discusses the achievements of China's market regulation system during the "14th Five-Year Plan" period, emphasizing the balance between regulatory norms and development promotion to enhance market vitality and fairness [1][3]. Group 1: Market Environment and Business Vitality - Since the beginning of the "14th Five-Year Plan," China has seen a net increase of 19.99 million enterprises and 33.946 million individual businesses [3]. - The market regulation authority has optimized the regulatory mechanisms, providing a fair competition environment that effectively stimulates the development and innovation of business entities [3]. - The reform of the registered capital subscription system has improved the quality of registered capital, while the implementation of real-name registration has helped prevent malicious debt evasion [3][4]. Group 2: Business Operations and Efficiency - The process for business exit has been streamlined, allowing businesses to exit the market in as little as 21 days through simplified procedures [4]. - The time required to open a restaurant has been reduced from 37 days to 15 days, and the number of documents needed for business information changes has been cut from 23 to 6 [4]. Group 3: Regulatory Enforcement and Market Order - During the "14th Five-Year Plan," market regulatory authorities handled 89.028 million complaints, recovering economic losses of 21.71 billion yuan for consumers [5]. - The pharmaceutical industry in China ranks second globally, with approximately 30% of innovative drugs under research [5][6]. - The regulatory framework has been strengthened to combat local protectionism and market monopolies, with significant amendments to antitrust laws and the introduction of comprehensive competition review regulations [8][9]. Group 4: Future Directions and Market Integration - The market regulation authority aims to further eliminate local protection and market segmentation, ensuring a fair competitive environment for all business entities [9]. - Continuous efforts will be made to enhance the regulatory framework for the platform economy, focusing on maintaining order in online transactions and promoting a healthy market environment [9].

Group 1 - Since the beginning of the 14th Five-Year Plan, the number of new enterprises in China has increased by 19.999 million, with individual businesses increasing by 33.946 million [2] - During the 14th Five-Year Plan, national market regulatory authorities handled 89.028 million complaints and reports, recovering economic losses of 21.71 billion yuan for consumers [4] - The total number of national standards in China has reached over 47,000, with more than 13,000 new national standards released during the 14th Five-Year Plan [6] Group 2 - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research worldwide [8] - A total of 387 children's medicines and 147 rare disease medicines have been approved for market since the beginning of the 14th Five-Year Plan, effectively meeting the medication needs of key populations [8]

Core Viewpoint - The State Administration for Market Regulation has achieved significant progress in optimizing market supervision mechanisms during the "14th Five-Year Plan" period, enhancing the competitive environment for various business entities and stimulating their development and innovation capabilities [1]. Group 1: Market Entry Regulation - Market entry has become more standardized through reforms in the registration capital system, including the introduction of a maximum 5-year capital contribution period, which has improved the "gold content" of registered capital [1]. - The implementation of real-name registration for business licenses and verification of address information has helped prevent fraudulent registrations and debt evasion [1]. - A unified national "negative list for market access" has been published, and the registration of company names and business scopes has been optimized [1]. Group 2: Market Exit Regulation - The process for business deregistration has been streamlined, with improved administrative guidance to assist companies facing challenges such as shareholder disappearance and lost seals [2]. - A "one-stop service" platform for business deregistration has been established, facilitating collaboration among various government departments [2]. - Simplified deregistration procedures allow businesses without debts to exit the market in as little as 21 days [2]. Group 3: Business Efficiency - Efforts to reduce steps, time, and costs have led to a significant decrease in the time required to open a restaurant from 37 days to 15 days, and the number of required documents for business information changes has been reduced from 23 to 6 [3]. - The use of electronic business licenses has increased, with downloads reaching 370 million times and cumulative usage exceeding 600 million [3]. - The implementation of standardized administrative licensing in market regulation has further enhanced efficiency [3]. Group 4: Fairness in Regulation and Enforcement - The "double random, one public" regulatory approach has been expanded to minimize disruptions to normal business operations [4]. - A system for administrative enforcement discretion has been established to enhance the standardization of enforcement practices [4]. - Regular communication mechanisms with business entities have been established to address their concerns and improve the business environment [4].